GlassScriptPhysician profile
Shealinna Ge
NPI 1861057671
$2,560.55
in general payments reported to CMS, 2019-2025
21 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,105 · 2024: $1,337 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,362 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,361.56 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $679.11 | 2023-2024 | Sotyktu |
| Janssen Biotech, INC. | $486.23 | 2023-2024 | Tremfya, Simponi, Stelara |
| Merz North America, INC. | $275.16 | 2023-2024 | |
| Abbvie INC. | $232.48 | 2023-2025 | |
| Incyte Corporation | $167.34 | 2023-2024 | Opzelura |
| Lilly USA, LLC | $136.79 | 2023-2024 | Taltz |
| Regeneron Healthcare Solutions, INC. | $118.39 | 2023-2025 | Libtayo, Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.04 | 2023 | Spevigo |
| Revance Therapeutics, INC. | $44.27 | 2024 | Daxxify |
| Novartis Pharmaceuticals Corporation | $44.12 | 2024 | |
| Genzyme Corporation | $38.63 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $38.10 | 2024 | Cabtreo |
| Amgen INC. | $37.27 | 2024 | Otezla |
| Ucb, INC. | $32.82 | 2024-2025 | Bimzelx |
| Pfizer INC. | $29.39 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $28.48 | 2023 | Vtama |
| Biofrontera INC. | $19.58 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Botanix Sb INC | $18.55 | 2025 | Sofdra |
| Leo Pharma INC. | $17.10 | 2024 | Adbry |
| Celgene Corporation | $15.97 | 2024 | Sotyktu |
| Galderma Laboratories, L.P. | $13.73 | 2024 | Aklief |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shealinna Ge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.